3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
2
Status
Recruiting
2
Sponsor Class
OTHER
1
INDUSTRY
1
Study Type
Interventional
2
Sponsor
Cancer Type
CNS
11
Gynecologic
2
Genitourinary
2
Gastrointestinal
2
Breast
2
Thoracic
1
Sarcoma
1
Plasma cell
1
Other hematologic neoplasm
1
Lymphoid
1
Dermatologic
1
Conditions
Breast Neoplasms
27
Ovarian Neoplasms
15
Triple Negative Breast Neoplasms
14
Carcinoma, Non-Small-Cell Lung
13
Melanoma
10
Neoplasm Metastasis
9
Colorectal Neoplasms
8
Stomach Neoplasms
7
Pancreatic Neoplasms
7
Carcinoma, Renal Cell
5
Carcinoma, Hepatocellular
5
Urogenital Neoplasms
4
Multiple Myeloma
4
Uterine Cervical Neoplasms
3
Urinary Bladder Neoplasms
3
Lung Neoplasms
3
Head and Neck Neoplasms
3
Endometrial Neoplasms
3
Carcinoma, Transitional Cell
3
Carcinoma, Merkel Cell
3
Prostatic Neoplasms
2
Osteosarcoma
2
Lymphoma
2
Liver Neoplasms
2
Kidney Neoplasms
2
Glioblastoma
2
Fallopian Tube Neoplasms
2
Esophageal Neoplasms
2
Thyroid Carcinoma, Anaplastic
1
Squamous Cell Carcinoma of Head and Neck
1
Interventions
pembrolizumab
3
fludarabine
2
Paclitaxel
2
Gemcitabine
2
Cyclophosphamide
2
Azacitidine
2
vocimagene amiretrorepvec
1
temsirolimus
1
spartalizumab
1
sonidegib
1
sacituzumab govitecan
1
ruxolitinib
1
rucaparib
1
ridaforolimus
1
pazopanib
1
motexafin gadolinium
1
lenvatinib
1
durvalumab
1
depatuxizumab mafodotin
1
cediranib
1
cc-486
1
carboxyamido-triazole
1
abiraterone
1
Thalidomide
1
Temozolomide
1
Sorafenib
1
Sirolimus
1
Radiation
1
Quality of Life
1
Proton Pump Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Glioblastoma
×
fludarabine
×
Breast
×
Clear all
NCT07523529
2026-04-13
SELECT-2CAR
Beijing Biotech
Phase 1/2
Recruiting
72 enrolled
NCT07410494
2026-02-18
SELECT-CAR-NK
Essen Biotech
Phase 1/2
Recruiting
85 enrolled